Researchers report an increase in sexually transmitted shigellosis in the UK, warning about worsening drug resistance. Coverage highlights that the infection—spread through sexual contact—has grown in prevalence in England, rising by about a quarter since 2023. The reporting also states that experts describe the condition as becoming “virtually untreatable,” indicating that available treatments may be losing effectiveness due to resistant strains. The articles frame the concern around antimicrobial resistance and note that standard care options may be failing as the bacteria evolve. The reports emphasize that the trend is continuing and that public health awareness is needed. While the accounts focus on England and the recent change in prevalence, they do not provide detailed figures beyond the approximate increase since 2023, nor do they specify which treatments are affected or the exact resistance rates. Overall, the sources present a consistent picture: sexually transmitted shigellosis is increasing in prevalence and is becoming harder to treat because resistance to existing antibiotics is rising.